Literature DB >> 16616303

Medical treatment of noncicatricial alopecia.

Maria K Hordinsky1.   

Abstract

Androgenetic alopecia, alopecia areata, and telogen effluvium are the primary nonscarring alopecias found in clinical practice. Androgenetic alopecia is considered to be the most common form of human alopecia and is postulated to affect more than 50% of men by age 50. Alopecia areata affects up to 2% of the U.S. population. Telogen effluvium frequently occurs after major life events, such as a severe illness, childbirth, or high fever, and may be associated with the use of certain medications or iron deficiency, particularly in women. The focus of this review is on the medical treatment of these common hair loss conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616303     DOI: 10.1016/j.sder.2006.01.007

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  5 in total

Review 1.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

2.  Presence of Mast Cells and Mast Cell Degranulation in Scalp Biopsies of Telogen Effluvium.

Authors:  Shane A Grace; Angela M Sutton; Nina Abraham; Eric S Armbrecht; Claudia I Vidal
Journal:  Int J Trichology       Date:  2017 Jan-Mar

3.  Potential applications of topical oxygen therapy in dermatology.

Authors:  Luigi Bennardo; Ester Del Duca; Stefano Dastoli; Giusy Schipani; Elisabetta Scali; Martina Silvestri; Steven P Nisticò
Journal:  Dermatol Pract Concept       Date:  2018-10-31

Review 4.  Design of In Vitro Hair Follicles for Different Applications in the Treatment of Alopecia-A Review.

Authors:  Matej Žnidarič; Žan Michel Žurga; Uroš Maver
Journal:  Biomedicines       Date:  2021-04-16

5.  Usefulness of high-frequency ultrasonography in the assessment of alopecia areata - comparison of ultrasound images with trichoscopic images.

Authors:  Dominik Mikiel; Adriana Polańska; Ryszard Żaba; Zygmunt Adamski; Aleksandra Dańczak-Pazdrowska
Journal:  Postepy Dermatol Alergol       Date:  2021-01-18       Impact factor: 1.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.